Plasma osteoprotegerin as a biomarker of poor glycaemic control that predicts progression of albuminuria in type 2 diabetes mellitus: A 3-year longitudinal cohort study-Reference-Cited by-同舟云学术

Plasma osteoprotegerin as a biomarker of poor glycaemic control that predicts progression of albuminuria in type 2 diabetes mellitus: A 3-year longitudinal cohort study

Published:2020-03 Issue: Volume:161 Page:107992
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Moh Angela Mei Chung,Pek Sharon Li Ting,Liu Jianjun,Wang Jiexun,Subramaniam Tavintharan,Ang Keven,Sum Chee Fang,Kwan Pek Yee,Lee Simon Biing Ming,Tang Wern Ee,Lim Su Chi

Funder

Singapore National Medical Research Council Grants

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference37 articles.

1. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159–67.

2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–53.

3. Health Promotion Board of Singapore.Information paper on diabetes in Singapore, November 14, 2011. Available from: https://www.nrdo.gov.sg/docs/librariesprovider3/default-document-library/diabetes-info-paper-v6.pdf?sfvrsn=0.

4. Plasma adiponectin levels and type 2 diabetes risk: a nested case-control study in a Chinese population and an updated meta-analysis;Wang;Sci Rep,2018

5. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study;Doi;Diabetes Care,2005

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RANKL/RANK contributes to the pathological process of type 2 diabetes mellitus through TRAF3 activation of NIK;International Immunopharmacology;2024-12

2. Cardiometabolic Effects of Denosumab in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression: RCT;The Journal of Clinical Endocrinology & Metabolism;2024-01-05

3. Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease;Current Obesity Reports;2023-05-19

4. Biochemical Markers of Bone Fragility in Patients With Diabetes;The Journal of Clinical Endocrinology & Metabolism;2023-05-08

5. RANKL inhibition: a new target of treating diabetes mellitus?;Therapeutic Advances in Endocrinology and Metabolism;2023-01